Bio Business Solutions, Equipment & Supplies

Illumina

We are excited to announce that CLSA is now offering its members a program through Illumina for gene sequencing solutions that can offer substantial savings to first time Illumina customers. Illumina technology is responsible for generating more than 90% of the world’s sequencing data. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. This savings program, through BIO Business Solutions®, is the result of collaboration between CLSA and the Biotechnology Innovation Organization (BIO), the world’s largest biotechnology trade association.

Member companies can realize the following benefits of the Illumina program:

  • Exclusive rebates on the following benchtop sequencing instrumentation for first-time Illumina customers
Low-throughput Instruments
MiSeq® Allows small genome sequencing and assembly, and enables detection of targeted variants with unmatched accuracy
MiSeqDx® First FDA cleared IVD platform with a growing menu of assays that enables clinical laboratories to create and deploy NGS based molecular diagnostic testing in their labs
MiSeq FGx A compact, fully validated NGS platform for forensic genomics applications
MiniSeq Flexible and affordable system that allows researchers to transition easily between sequencing projects for both DNA and RNA
Mid-throughput Instruments
NextSeq®500 Enables rapid sequencing of exomes, targeted panels, and transcriptions
NextSeq®550 Enables NGS and Cytogenetic Array Scanning on one instrument

For Research Use Only. Not for use in diagnostic procedures.
For more information about the program and a full list of benefits, please visit http://bbs.bio.org/content/illumina

National Contact
Danae Kapsch
(858) 255-5691
dkapsch@illumina.com